Metabolomics-Based Detection of Colorectal Cancer
In this study, metabolite profiling analysis will be carried out on colon cancer patients at
the time of diagnosis and during the course of treatment, using patient tissue and serum
samples. Samples of serum (1 ml) and tissue specimens (50 mg each) from colorectal cancer
patients (stages I-IV) and serum samples from an equal number of age and gender-matched
healthy controls will be obtained under identical (8-hour overnight fasting) conditions.
Metabolic profiles will be identified using the NMR and MS instruments located in Purdue's
on-campus NMR and MS facilities. Multivariate statistical analyses will be used to monitor
changing metabolite profiles that indicate changes in disease status. We anticipate that
putative biomarkers will be easier to identify in the cancerous tissue, and the
concentrations of these metabolites will then be quantified in the patients' serum, that
ultimately would allow for easier detection of colon cancer.
Time Perspective: Prospective
•Perform metabolic profiling of tissue,serum & urine from pts w/ colorectal cancer (stages I-IV), healthy controls & pts w/ colorectal polyps & correlate results.
Elena Chiorean, MD
United States: Institutional Review Board
|Indiana University Cancer Center||Indianapolis, Indiana 46202-5265|